Chris Miller, a partner in Troutman Pepper’s Emerging Companies + Venture Capital Group, was quoted in the March 24, 2023 BioPharma Dive article, “Biotech Startups Face ‘Series A Cliff’ as Venture Capital Stays Cautious.”

“These companies are running out of money,” said Chris Miller, a partner with Troutman Pepper who works on private funding deals. “That’s a much bigger issue in biotech right now” than SVB, he added.

…

“Finding new investors, or significant chunks of new capital, is very difficult,” said Miller. “That is still the big concern.”

Insight Industries + Practices